Lennox Gastaut Sendromu
Özet
Lennox-Gastaut Sendromu (LGS), çocukluk çağında başlayan; dirençli nöbetler, tipik EEG bulguları ve bilişsel gerilik ile karakterize, morbiditesi yüksek ciddi bir epileptik ensefalopatidir. Etiyolojisinde genetik, metabolik ve yapısal faktörler rol oynasa da vakaların önemli bir kısmı kriptojeniktir. Tedavisi antiepileptik ilaçlar, ketojenik diyet ve cerrahi yöntemleri içermekle birlikte, tam nöbet kontrolü sağlamak genellikle oldukça zordur. Hastalığın uzun dönem prognozu genellikle kötüdür ve hastaların yaşam kalitesi ile bilişsel işlevleri üzerinde ciddi olumsuz etkiler bırakmaktadır.
Lennox-Gastaut Syndrome (LGS) is a severe childhood-onset epileptic encephalopathy characterized by refractory seizures, specific EEG findings, and cognitive impairment. Although its etiology involves genetic, metabolic, and structural factors, a significant portion of cases remain cryptogenic. Management involves antiepileptic drugs, ketogenic diet, and surgical options, yet achieving complete seizure control remains challenging. The long-term prognosis is generally poor, often resulting in significant negative impacts on the quality of life and cognitive functioning of patients.
Referanslar
Crespel A, Gelisse P, Macorig G, Nikanorova M, Ferlazzo E, Genton P. Lennox-Gastaut syndrome. In: Bureau M, Genton P, Dravet C, Delgado-Escueta AV, Guerrini R, Tassinari CA, et al., editors. Epileptic syndromes in infancy, childhood and adolescence. 6th ed. Arcueil: John Libbey Eurotext; 2019.
Cross JH, Auvin S, Falip M, Striano P, Arzimanoglou A. Expert opinion on the management of Lennox-Gastaut syndrome: treatment algorithms and practical considerations. Front Neurol. 2017;8:505.
Smith KM, Britton JW, Cascino GD. Late-onset Lennox-Gastaut syndrome: diagnostic evaluation and outcome. Neurol Clin Pract. 2018;8(5):397–402.
Arzimanoglou A, French J, Blume WT, et al. Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol. 2009;8(1):82–93.
Camfield PR. Definition and natural history of Lennox Gastaut syndrome. Epilepsia 2011; 52(Suppl 5):3–9.
Asadi-Pooya AA: Lennox-Gastaut syndrome: a comprehensive review . Neurol Sci. 2018; 39: 403-414.
Strzelczyk A, Schubert-Bast S. Expanding the Treatment Landscape for Lennox-Gastaut Syndrome: Current and Future Strategies. CNS Drugs. 2021;35(1):61-83.
Ferlazzo E, Nikanorova M, Italiano D, et al. Lennox-Gastaut syndrome in adulthood: clinical and EEG features. Epilepsy Res 2010; 89(2–3):271–277
Widdess-Walsh P, Dlugos D, Fahlstrom R, EPGP Investigators et al. Lennox-Gastaut syndrome of unknown cause: phenotypic characteristics of patients in the Epilepsy Phenome/Genome Project. Epilepsia 2013; 54(11):1898–1904.
Janve VS, Hernandez CC, Verdier KM, Hu N, Macdonald RL. Epileptic encephalopathy de novo GABRB mutations impair γ-aminobutyric acid type A receptor function. Ann Neurol. 2016;79(5):806-825.
Marini C, Romoli M, Parrini E, et al. Clinical features and outcome of 6 new patients carrying de novo KCNB1 gene mutations. Neurol Genet. 2017; 11;3(6):e206.
Selmer KK, Lund C, Brandal K, Undlien DE, Brodtkorb E. SCN1A mutation screening in adult patients with Lennox–Gastaut syndrome features. Epilepsy Behav 2009; 16(3):555–557.
Lund C, Brodtkorb E, Oye AM, Rosby O, Selmer KK. CHD2 mutations in Lennox-Gastaut syndrome. Epilepsy Behav 2004; 33:18–21
Terrone G, Bienvenu T, Germanaud D, et al. A case of Lennox-Gastaut syndrome in a patient with FOXG1-related disorder. Epilepsia 2014; 55(11): e116–e119
von Spiczak S, Helbig KL, Shinde DN, et al. Epi4K Consortium; EuroEPINOMICS-RES NLES Working Group. DNM1 encephalopathy: A new disease of vesicle fission. Neurology. 2017; 89(4):385-394.
Cai K, Wang J, Eissman J, et al. A missense mutation in SLC6A1 associated with Lennox-Gastaut syndrome impairs GABA transporter 1 protein trafficking and function. Exp Neurol. 2019; 320: 112973.
Lammertse HCA, van Berkel AA, Iacomino M, et al. Homozygous STXBP1 variant causes encephalopathy and gain-of-function in synaptic transmission. Brain. 2020;143(2):441-451.
Nieh SE, Sherr EH. Epileptic encephalopathies: new genes and new pathways. Neurotherapeutics 2014; 11(4):796–806.
Hancock EC, Cross HH. Treatment of Lennox-Gastaut syndrome. Cochrane Database Syst Rev. 2009;(3):CD003277.
Pillay N, Archer JS, Badawy RA, Flanagan DF, Berkovic SF, Jackson G. Networks underlying paroxysmal fast activity and slow spike and wave in Lennox-Gastaut syndrome. Neurology 2013; 81(7): 665–673.
Warren AE, Abbott DF, Vaughan DN, Jackson GD, Archer JS. Abnormal cognitive network interactions in Lennox-Gastaut syndrome: A potential mechanism of epileptic encephalopathy. Epilepsia. 2016 May;57(5):812-22.
Archer JS, Warren AE, Jackson GD, Abbott DF. Conceptualizing lennox-gastaut syndrome as a secondary network epilepsy. Front Neurol. 2014;5:225.
Intusoma U, Abbott DF, Masterton RA, et al. Tonic seizures of Lennox-Gastaut syndrome: periictal single-photon emission computed tomography suggests a corticopontine network. Epilepsia. 2013;54(12):2151-7.
Bare MA, Glauser TA, Strawsburg RH. Need for electroencephalogram video confirmation of atypical absence seizures in children with Lennox-Gastaut syndrome. J Child Neurol 1998; 13(10): 498–500.
Camfield PR. Definition and natural history of LennoxGastaut syndrome. Epilepsia 2011; 52(Suppl 5):3–9.
Hoffmann-Riem M, Diener W, Benninger C, et al. Nonconvulsive status epilepticus—a possible cause of mental retardation in patients with LennoxGastaut syndrome. Neuropediatrics 2000; 31(4):169–174.
Asadi-Pooya AA, Dlugos D, Skidmore C, Sperling MR. Atlas of electroencephalography, 3rd edition. Epileptic Disord 2017; 19(3):384.
Asadi-Pooya AA, Sharifzade M. Lennox-Gastaut syndrome in south Iran: electro-clinical manifestations. Seizure 2012; 21(10):760–763.
Goldsmith IL, Zupanc ML, Buchhalter JR. Long-term seizure outcome in 74 patients with Lennox-Gastaut syndrome: effects of incorporating MRI head imaging in defining the cryptogenic subgroup. Epilepsia 2000; 41(4): 395–399.
Strzelczyk A, Schubert-Bast S. Expanding the Treatment Landscape for Lennox-Gastaut Syndrome: Current and Future Strategies. CNS Drugs. 2021; 35(1):61-83.
Jahngir MU, Ahmad MQ, Jahangir M. Lennox-Gastaut Syndrome: In a Nutshell. Cureus. 2018;10(8):e3134.
Michoulas A, Farrell K. Medical management of LennoxGastaut syndrome. CNS Drugs 2010; 24(5):363–374.
Ferrie CD, Patel A. Treatment of Lennox-Gastaut syndrome (LGS). Eur J Paediatr Neurol. 2009;13(6):493–504.
Ng YT, Conry JA, Drummond R, Stolle J, Weinberg MA. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology. 2011;77(15):1473–81.
Conry JA, Ng YT, Kernitsky L, Mitchell WG, Veidemanis R, Drummond R, et al. Stable dosages of clobazam for LennoxGastaut syndrome are associated with sustained drop-seizure and total-seizure improvements over 3 years. Epilepsia. 2014;55(4):558–67.
Motte J, Trevathan E, Arvidsson JFV, Barrera MN, Mullens EL, Manasco P. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. N Engl J Med. 1997;337(25):1807–12.
Coppola G, Caliendo G, Veggiotti P, Romeo A, Tortorella G, De Marco P, et al. Topiramate as add-on drug in children, adolescents and young adults with Lennox-Gastaut syndrome: an Italian multicentric study. Epilepsy Res. 2002;51(1–2):147–53.
Heyman E, Levin N, Lahat E, Epstein O, Gandelman-Marton R. Eficacy and safety of felbamate in children with refractory epilepsy. Eur J Paediatr Neurol. 2014;18(6):658–62.
Shah YD, Singh K, Friedman D, Devinsky O, Kothare SV. Evaluating the safety and efcacy of felbamate in the context of a black box warning: a single center experience. Epilepsy Behav. 2016;56:50–3.
Bast T, Richter S, Ebinger F, Rating D, Wiemer-Kruel A, Schubert-Bast S. Efcacy and tolerability of methylprednisolone pulse therapy in childhood epilepsies other than infantile spasms. Neuropediatrics. 2014;45(6):378–85.
Bakker DP, Catsman-Berrevoets CE, Neuteboom RF. Efectiveness of a hybrid corticosteroid treatment regimen on refractory childhood seizures and a review of other corticosteroid treatments. Eur J Paediatr Neurol. 2015;19(5):553.
Kim HJ, Kim SH, Kang HC, Lee JS, Chung HJ, Kim HD. Adjunctive levetira-cetam treatment in pediatric Lennox-Gastaut syndrome. Pediatr Neurol 2014;51(4):527–31.
Rathaur BP, Garg RK, Malhotra HS, Kumar N, Sharma PK, Verma R, Uniyal R. Lennox-Gastaut Syndrome: A Prospective Follow-up Study. J Neurosci Rural Pract. 2017;8(2):225-227.
You SJ, Kang HC, Kim HD, Lee HS, Ko TS. Clinical efficacy of zonisamide in Lennox-Gastaut syndrome: Korean multicentric experience. Brain Dev. 2008; 30(4):287-90.
Balagura G, Riva A, Marchese F, Verrotti A, Striano P. Adjunctive rufnamide in children with Lennox-Gastaut syndrome: a literature review. Neuropsychiatr Dis Treat. 2020;16:369–79.
Striano P, McMurray R, Santamarina E, Falip M. Rufnamide for the treatment of Lennox-Gastaut syndrome: evidence from clinical trials and clinical practice. Epileptic Disord. 2018;20(1):13–29.
Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, et al. Efect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N Engl J Med. 2018;378(20):1888–97.
Thiele EA, Marsh ED, French JA, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10125):1085–96
Laux LC, Bebin EM, Checketts D, et al. Long-term safety and efcacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results. Epilepsy Res. 2019; 154:13–20.
Bialer M, Perucca E. Does cannabidiol have antiseizure activity independent of its interactions with clobazam? An appraisal of the evidence from randomized controlled trials. Epilepsia. 2020; 61(6):1082–9.
Lattanzi S, Brigo F, Trinka E, et al. Adjunctive cannabidiol in patients with dravet syndrome: a systematic review and meta-analysis of efcacy and safety. CNS Drugs. 2020;34(3):229–41.
Lattanzi S, Trinka E, Striano P, et al. Cannabidiol efcacy and clobazam status: a systematic review and meta-analysis. Epilepsia. 2020;61(6):1090.
Polster T. Individualized treatment approaches: Fenfuramine, a novel antiepileptic medication for the treatment of seizures in Dravet syndrome. Epilepsy Behav. 2019; 91:99–102.
Zogenix. Zogenix announces positive top-line results from global pivotal phase 3 trial of FINTEPLA® for the treatment of Lennox Gastaut syndrome. 2020. https://zogenixinc.gcs-web.com/newsreleases/news-release-details/zogenix-announces-positive-topline-results-global-pivotal-phase.
Clinicaltrials.gov. NCT02834793: study of perampanel as adjunctive treatment for inadequately controlled seizures associated with Lennox-Gastaut syndrome. https://clinicaltrials.gov/ ct2/show/NCT02834793.
Halford J, Sperling M, Arkilo D, et al. A phase 1b/2a study of soticlestat (TAK-935/OV935) as adjunctive therapy in adults with developmental and/or epileptic encephalopathies (DEE) (4715). Neurology. 2020;94(15 Supplement):4715.
Hadera MG, Faure J-B, Berggaard N, Tefera TW, Nehlig A, Sonnewald U. The anticonvulsant actions of carisbamate associate with alterations in astrocyte glutamine metabolism in the lithium–pilocarpine epilepsy model. J Neurochem. 2015;132(5):532–45.
Devinsky O, Segal E, Chez M, Waksman J, Lappalainen J, Masuoka L. Open-label trial of ganaxolone in children with Lennox-Gastaut syndrome. American Epilepsy Society (Abstract 3.427). 2017. https://www.aesnet.org/meetings_event s/annual_meeting_abstracts/view/392831.
Kim HJ, Kim HD, Lee JS, Heo K, Kim DS, Kang HC. Longterm prognosis of patients with Lennox-Gastaut syndrome in recent decades. Epilepsy Res 2015; 110:10–19.
Piña-Garza JE, Montouris GD, Vekeman F, et al. Assessment of treatment patterns and healthcare costs associated with probable Lennox-Gastaut syndrome. Epilepsy Behav 2017; 73:46–5.
